Ohcanbohtosat - James A Davis

  • Čájehuvvo 1 - 18 / 18
Aiddostahte ozu
  1. 1
    Arabidopsis Ca2+-ATPases 1, 2, and 7 in the endoplasmic reticulum contribute to growth and pollen fitness

    Arabidopsis Ca2+-ATPases 1, 2, and 7 in the endoplasmic reticulum contribute to growth and pollen fitness Dahkki Maryam Rahmati Ishka, Elizabeth Brown, Alexa Rosenberg, Shawn M. Romanowsky, James A Davis, Won‐Gyu Choi, Jeffrey F. Harper

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy

    Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy Dahkki James A. Davis, Douglas W. Sborov, William Wesson, Kelley Julian, Al‐Ola Abdallah, Joseph P. McGuirk, Nausheen Ahmed, Hamza Hashmi

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Iodinated cyanine dyes: a new class of sensitisers for use in NIR activated photodynamic therapy (PDT)

    Iodinated cyanine dyes: a new class of sensitisers for use in NIR activated photodynamic therapy (PDT) Dahkki Jordan Atchison, Sukanta Kamila, Heather Nesbitt, Kieran A. Logan, Dean Nicholas, Colin Fowley, James A. Davis, John F. Callan, A. P. McHale, John F. Callan

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Drinking water treatment by multistage filtration on a household scale: Efficiency and challenges

    Drinking water treatment by multistage filtration on a household scale: Efficiency and challenges Dahkki Raphael Corrêa Medeiros, Natália de Melo Nasser Fava, Bárbara Luíza Souza Freitas, Lyda Patrícia Sabogal-Paz, Maria Teresa Hoffmann, James A. Davis, Pilar Fernández‐Ibáñez, John Byrne

    Almmustuhtton 2020
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies Dahkki James A. Davis, Katelynn Granger, Kiera Roubal, Deidra Smith, Kelly J Gaffney, Mary McGann, Alyssa Cendagorta, Aswani Thurlapati, Amanda Herbst, Lindsey Hendrickson, Hamza Hashmi, Brian T. Hess

    Almmustuhtton 2022
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

    Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma Dahkki James A. Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P. McGuirk, Xuefei Jia, Shahzad Raza, Jack Khouri, Jason Valent, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

    Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma Dahkki Danai Dima, James A. Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Faiz Anwer, Al‐Ola Abdallah, Hamza Hashmi

    Almmustuhtton 2023
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world multicentre study

    Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the <scp>KarMMa</scp>‐1 trial eligibility criteria: A real‐world mul... Dahkki Danai Dima, Aliya Rashid, James A. Davis, Leyla Shune, Al‐Ola Abdallah, Hong Li, Shaun DeJarnette, Jack Khouri, Louis Williams, Hamza Hashmi, Shahzad Raza, Joseph P. McGuirk, Faiz Anwer, Nausheen Ahmed

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

    Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma Dahkki James A. Davis, Jordan Snyder, Mikhaila L. Rice, Donald C. Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria R. Nachar

    Almmustuhtton 2025
    Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

    Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy Dahkki Danai Dima, Al‐Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis O. Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma Dahkki William Wesson, Danai Dima, Nahid Suleman, M Saif, Carine Tabak, Emerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, Aliya Rashid, Al‐Ola Abdallah, Fauzia Ullah, Leyla Shune, Muhammad Umair Mushtaq, Shahzad Raza, Joseph P. McGuirk, Mehdi Hamadani, Faiz Anwer, Hamza Hashmi, Nausheen Ahmed

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience

    Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortiu... Dahkki Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castañeda Puglianini, Ciara L. Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James A. Davis, Charlotte B Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson, Aimaz Afrough, Danai Dima, Jack Khouri, Joseph P. McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

    Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel Dahkki Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castañeda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan M. Herr, Hamza Hashmi, Peter A. Forsberg, Douglas W. Sborov, Larry Anderson, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji Kumar, Doris K. Hansen

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy Dahkki Christopher Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi, Leyla Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B Wagner, Mehmet H. Kocoglu, Aaron P. Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Castañeda Puglianini

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

    Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment Dahkki Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter M. Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David B. Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara L. Freeman, Melissa Alsina, Frederick L. Locke, Rebecca Gonzalez, Yi Lin, Joseph P. McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen

    Almmustuhtton 2023
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

    Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myelom... Dahkki Nico Gagelmann, Danai Dima, Maximilian Merz, Hamza Hashmi, Nausheen Ahmed, Natalia Tovar, Aina Oliver‐Cáldes, Friedrich Stölzel, Kristin Rathje, Luise Fischer, Patrick Born, Lisa Schäfer, Anca‐Maria Albici, Natalie Schub, Shlomit Kfir‐Erenfeld, Miri Assayag, Nathalie Asherie, Gerald Wulf, Soraya Kharboutli, Fabian Müller, Leyla Shune, James A. Davis, Faiz Anwer, Vladan Vučinić, Uwe Platzbecker, Francis Ayuk, Nicolaus Kröger, Jack Khouri, Carmelo Gurnari, Joseph P. McGuirk, Polina Stepensky, Al‐Ola Abdallah, Carlos Fernández de Larrea

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium

    Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium Dahkki Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castañeda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin

    Almmustuhtton 2024
    Viečča ollesdeavstta Viečča ollesdeavstta
    Carta
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy

    Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy Dahkki Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A.W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver‐Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vučinić, Soraya Kharboutli, Ben‐Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca‐Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad Raza, Joseph P. McGuirk, Zahra Mahmoudjafari, Kimberly Green, Cyrus Khandanpour, Marcel Teichert, Barbara Jeker, Michèle J. Hoffmann, Nicolaus Kröger, Bastian von Tresckow, Carlos Fernández de Larrea, Thomas Pabst, Al‐Ola Abdallah, Nico Gagelmann

    Almmustuhtton 2024
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: